ペプチド治療市場：技術、薬剤クラス別、投与経路、用途、エンドユーザー、製造タイプ別-2024～2030年の世界予測

ペプチド治療市場規模は2023年に330億6,000万米ドルと推定され、2024年には357億6,000万米ドルに達し、CAGR 8.35%で2030年には579億7,000万米ドルに達すると予測されています。

ペプチド治療では、アミノ酸の短い鎖を使用して、さまざまな病気や病状を治療またはコントロールします。これらの生物学的に活性な分子はユニークな特性を持っており、効率的な医薬品開発や製薬研究の選択肢となっています。がんや糖尿病を含む慢性疾患の急増は、効果的な治療オプションの必要性と、標的治療につながるタンパク質間相互作用の理解を深める必要性を高めています。研究開発活動への投資が増加し、治療候補の臨床パイプラインが充実してきた結果、新規のペプチド治療が開発されています。しかし、ペプチド特有の不安定性や製造コストの高さは、ペプチド治療の開発に悪影響を及ぼす可能性があります。さらに、近年のドラッグデリバリーシステムの発展や新規ペプチドの開発により、ペプチドの潜在的な用途が拡大することが期待されます。

技術：複雑なペプチドの合成における固相アプローチの利用率の上昇

ハイブリッド相アプローチは、液相合成と固相合成の特徴を組み合わせ、ペプチド生産の高純度レベルを維持しながら効率とスケーラビリティを高める。この手法は、従来の手法に伴う課題を克服できるため、複雑なペプチドや大きなペプチドを開発する際に好まれています。液相ペプチド合成（LPPS）は、様々な化学反応を用いて溶液中でアミノ酸を結合させる。LPPSは固相法に比べて反応速度が比較的速いため、短鎖から中鎖のペプチドの小規模生産に適しています。固相ペプチド合成（SPPS）は、最初のアミノ酸を固体の樹脂支持体に付着させ、その後、後続のアミノ酸を順次添加します。この方法は、より長く複雑なペプチドを合成でき、精製が容易でスケーラビリティがあるため、広く好まれています。ハイブリッド相技術は、液相と固相の長所を併せ持つため、大きなペプチドや複雑なペプチドを開発するのに適しています。液相合成は、主に小規模の短鎖から中鎖のペプチド生産に用いられます。固相ペプチド合成は、より長く複雑なペプチドを合成する汎用性がある一方で、精製が容易でスケーラビリティのあるオプションを提供するため、広く支持されています。

薬剤クラス：1型と2型糖尿病のグルコース代謝を調節するインスリンの必要性の高まり

副腎皮質刺激ホルモン（ACTH）は、下垂体前葉から分泌・産生されるポリペプチドホルモンです。治療上、ACTHはコルチゾール産生を刺激する必要がある特定の疾患の管理に利用されます。これには、副腎不全や特定の炎症性疾患など、コルチゾールレベルの上昇に反応する疾患の治療が含まれます。治療に使用される外因性製剤は、副腎皮質に直接的な刺激を与え、発生するACTHの作用をシミュレートしてコルチゾールの分泌を促し、それによって抗炎症作用と免疫賦活作用を発揮します。カルシトニンは、カルシウムとリンの代謝に重要です。ヒトでは主に甲状腺傍濾胞細胞によって産生されます。サケ由来または合成されたカルシトニンの治療型は、主に閉経後骨粗鬆症、ページェット病、高カルシウム血症の治療に利用されています。破骨細胞の活性を阻害することにより、カルシトニンは骨吸収を抑制し、血中カルシウム濃度を低下させる。インスリンは、膵臓のβ細胞によって産生されるグルコース代謝の調節に重要な基本的ペプチドホルモンであり、血液から筋肉、肝臓、脂肪細胞へのグルコースの取り込みを促進します。治療面では、インスリンは、1型と2型糖尿病の管理に不可欠です。リュープロレリンは、ゴナドトロピン放出ホルモン（GnRH）の合成アナログであり、連続投与で使用される場合、強力なゴナドトロピン分泌阻害剤として機能します。男性では前立腺がん、女性では子宮内膜症や子宮筋腫などのホルモン反応性がんの治療に用いられます。オクトレオチドは、天然ホルモンであるソマトスタチンの合成オクタペプチド類似体であり、薬理作用は類似しているが、より長く持続します。オクトレオチドは主に、成長ホルモンの過剰産生を特徴とする先端巨大症の管理、カルチノイド腫瘍や血管作動性腸管ペプチド分泌腺腫（VIP腫）など、ホルモンを分泌する特定のタイプの腫瘍によって引き起こされる症状の制御に使用されます。オクトレオチドは、成長ホルモン、ガストリン、インスリン、グルカゴンなどのさまざまなホルモンの分泌を阻害することによって作用します。バソプレシンは抗利尿ホルモン（ADH）とも呼ばれ、下垂体後葉から分泌され視床下部で産生されるペプチドホルモンです。ADHは、腎臓の集合管における水分の再吸収を増加させることにより、身体の水分貯留を調節する上で重要です。治療面では、バソプレッシンとそのアナログは、過剰な口渇と多量の希釈尿の産生を特徴とする糖尿病性腎不全の治療、血管収縮作用による静脈瘤出血の管理に使用されます。

投与経路：急性期病院における即効性と有効性から、静脈内投与が増加傾向にあります。

ペプチド治療の静脈内投与は、血流に直接デリバリーされ、即時のバイオアベイラビリティを促進します。このルートは、消化管からの吸収が悪かったり、他のルートで投与した場合に代謝されやすいペプチドに特に有利です。静脈内投与は、急性期医療で使用されるペプチドや迅速な作用発現が必要とされるペプチドにとっては極めて重要です。しかし、投与には臨床インフラと熟練したスタッフが必要であり、外来患者や慢性治療への適用が制限される可能性があります。鼻腔と肺への投与は、ペプチド治療に非侵襲的な投与方法を提供し、効率的な吸収と特定の症状に対する即効性をもたらすことができます。経鼻投与は、鼻から脳への経路を利用して中枢神経系を標的とするペプチドに特に適しています。肺投与は、呼吸器疾患を対象としたペプチドに理想的で、肺への直接送達を可能にします。どちらの方法も初回通過代謝をバイパスするため、治療のバイオアベイラビリティを高める可能性があります。経口投与は、その利便性、患者のコンプライアンス、費用対効果から、ドラッグデリバリーには好ましい経路です。ペプチドは消化管内で酵素分解を受けやすく、腸管上皮を通過する透過性が低いです。酵素阻害剤、浸透促進剤、ナノ粒子デリバリーシステムなど、薬学の進歩は、程度の差こそあれ、これらのハードルを克服する可能性を示しています。ペプチド治療の経皮投与は、注射や特殊な吸入装置を必要としないため、有効性と患者のコンプライアンスとの間で説得力のあるバランスを記載しています。このルートは、薬剤の徐放性を必要とする慢性疾患には特に有利です。マイクロニードル、イオントフォレーシス、超音波などの経皮技術の進歩により、皮膚バリアを通過するペプチドの輸送が改善されてきました。皮膚透過性とペプチドの安定性を高める製剤戦略は、経皮吸収型製剤の開発を成功させるための中心的な要素です。

用途：血圧調節に関与する内因性ペプチドの作用をシミュレートするための循環器疾患におけるペプチド治療の使用拡大

循環器疾患において、ペプチド治療はその正確な作用機序により、血管機能、血圧、凝固経路を効果的に調節できることから使用されてきました。抗凝固ペプチドは、心筋梗塞や脳卒中の重大な危険因子である血栓症を予防するために利用されています。胃腸（GI）障害では，ペプチド治療は標的治療の選択肢を提示します。さらに、消化管ホルモンを模倣または阻害するペプチドは、消化管内の運動、吸収、分泌を調節し、様々な障害の症状に対応することができます。その標的作用は、ホルモンバランスの乱れや消化管関連疾患の混乱に起因する症状の管理に役立ちます。ペプチド治療感染性疾患、特に抗生物質耐性が増加する時代において、感染性疾患の管理に新たなアプローチをもたらします。抗菌ペプチド（AMP）は幅広い抗菌活性を持ち、細菌、真菌類、さらにはウイルスの細胞膜を破壊することでその一部を標的とします。その作用機序は耐性菌発生の可能性を低くし、薬剤耐性感染症との闘いにおいて重要な候補となります。神経疾患においては、血液脳関門（BBB）を通過し、中枢神経系（CNS）に直接神経保護効果をもたらす可能性が検討されています。ペプチドは特定の神経伝達系を標的としており、アルツハイマー病、パーキンソン病、多発性硬化症などの疾患治療の機会を提供しています。腫瘍学では、ペプチド治療が急成長しているセグメントであり、がん細胞に対する直接的な細胞毒性作用、血管新生の阻害、標的ドラッグデリバリーのためのビヒクルなど、ペプチドの抗がん特性が調査しています。腫瘍ホーミングペプチドは、化学療法剤や放射性核種を腫瘍細胞に選択的に送達することができ、健康な組織へのダメージを最小限に抑え、治療効果を高めることができます。

エンドユーザー：病院やクリニックでのペプチド治療の使用拡大による患者の状態への対応と管理

病院やクリニックでは、ペプチド治療は主に患者の直接治療に利用されています。がん、代謝異常、心血管疾患、感染症など、多くの疾患の治療に用いられています。ペプチド医薬品は、その高い特異性と効能、比較的低い毒性により、従来の低分子医薬品と比較して、より少ない副作用でより高い効果が期待できる治療への標的アプローチを記載しています。病院やクリニックにおけるペプチド医薬品の応用は、ペプチド工学やドラッグデリバリー技術の進歩とともに絶えず進化しており、その有効性と患者のコンプライアンスを高めています。長期療養施設では、患者の健康を長期にわたって確保する治療が優先され、治療よりも管理に重点が置かれることが多いです。長期療養施設で使用されるペプチド治療は、介護環境に対応するため、副作用を最小限に抑え、投与頻度を少なくする必要があります。研究室はペプチド治療開発の初期段階において極めて重要です。研究者は、新しい生理活性ペプチドを同定し、その作用機序を解明し、その特性を治療用に最適化することに注力しています。これには、最先端の分子生物学、生化学、薬理学の技術を駆使し、ペプチド候補の設計、合成、活性評価を行う。

製造タイプ：専門的な製造能力と迅速な生産規模拡大の必要性からCMOの採用が増加

製造受託機関は、ペプチド治療の製造に不可欠なサービスを提供し、社内に必要な製造設備を持たないか、コアコンピタンスに集中するために製造を外注することを選択した製薬会社やバイオテクノロジー企業にサービスを提供しています。CMOは、研究用の少量のペプチド合成から商業用の大量生産まで、様々なサービスを提供しています。CMOは、ペプチド治療の効率的でコンプライアンスに適合した製造に必要な技術的専門知識、高度な技術、規制に関する知識を有しています。自社製造とは、製薬会社やバイオテクノロジー会社がペプチド治療を製造するための設備や資源を持つことを指します。このアプローチにより、企業は生産工程、品質管理、サプライチェーン管理を直接管理することができ、外部供給業者への依存に伴うリスクを軽減できる可能性があります。大手の製薬会社は、必要なインフラや熟練した人材に投資する資金力を持ち、自社内に生産施設を設立することが多いです。このモデルは、研究開発活動と製造の緊密な統合を促進し、急速に発展する治療セグメントにおいて有利となります。

地域別洞察

南北アメリカでは、製薬産業が確立され、研究活動が活発化し、承認されたペプチド医薬品の数が増加しているため、ペプチド治療市場が発展しています。この地域の特許活動は注目に値し、複数の大手製薬会社がこの地域に本社を置いています。近年、革新的なペプチド製剤への投資が増加しており、新たな治療アプローチに対する市場の潜在力が高いことを示しています。慢性疾患の有病率の上昇、医療インフラの改善、ペプチド治療に関する意識の高まりが、アジア太平洋におけるペプチド治療市場の成長を後押ししています。さらに、ペプチドを生産するための効率的でスケーラブル、かつコスト効率の高い合成戦略の進歩や開発が進んでおり、ペプチド治療の世界の普及が見込まれています。ペプチド治療市場は、バイオテクノロジーにおける技術革新を支援し、ペプチド治療に関連する研究プロジェクトに資金を提供する規制の枠組みにより、欧州、中東、アフリカ地域で発展しています。欧州連合（EU）は、包括的な医療システムと高度な治療オプションに関する高い意識に支えられ、ペプチド治療の確立された市場を示しています。欧州医薬品庁（EMA）を通じたEUの規制枠組みは、ペプチドベースの医薬品の承認と監視に役立っています。アフリカ地域のペプチド治療市場は、研究活動の活発化と先進的な治療オプションに対する意識の高まりにより、現在着実に成長しています。

FPNVポジショニングマトリックス

FPNVポジショニングマトリックスはペプチド治療市場を評価する上で極めて重要です。事業戦略と製品満足度に関連する主要指標を調査し、ベンダーの包括的な評価を記載しています。この綿密な分析により、ユーザーは各自の要件に沿った十分な情報に基づいた意思決定を行うことができます。評価に基づき、ベンダーは成功の度合いが異なる4つの象限に分類されます。フォアフロント（F）、パスファインダー（P）、ニッチ（N）、バイタル（V）です。

市場シェア分析

市場シェア分析は、ペプチド治療市場におけるベンダーの現状について、洞察に満ちた詳細な調査を提供する包括的なツールです。全体的な収益、顧客基盤、その他の主要指標についてベンダーの貢献度を綿密に比較・分析することで、企業の業績や市場シェア争いの際に直面する課題について理解を深めることができます。さらに、この分析により、調査対象基準年に観察された累積、断片化の優位性、合併の特徴などの要因を含む、このセグメントの競合特性に関する貴重な考察が得られます。このような詳細レベルの拡大により、ベンダーはより多くの情報に基づいた意思決定を行い、市場で競争優位に立つための効果的な戦略を考案することができます。

本レポートは、以下の側面に関する貴重な洞察を提供しています。

1.市場の浸透度：主要企業が提供する市場に関する包括的な情報を提示しています。

2.市場の開拓度：有利な新興市場を深く掘り下げ、成熟市場セグメントにおける浸透度を分析しています。

3.市場の多様化：新製品の発売、未開拓の地域、最近の開発、投資に関する詳細な情報を記載しています。

4.競合の評価と情報：市場シェア、戦略、製品、認証、規制状況、特許状況、主要企業の製造能力について徹底的な評価を行います。

5.製品開発とイノベーション：将来の技術、研究開発活動、画期的な製品開発に関する知的洞察を記載しています。

本レポートは、以下のような主要な質問に対応しています。

1.ペプチド治療市場の市場規模と予測は？

2.ペプチド治療市場の予測期間中に投資を検討すべき製品、用途は何か？

3.ペプチド治療市場の技術動向と規制枠組みは？

4.ペプチド治療市場における主要ベンダーの市場シェアは？

5.ペプチド治療市場への参入に適した形態や戦略的手段は？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 慢性疾患の蔓延と効果的な治療法の必要性
    • 美容皮膚科におけるペプチドの急激な利用
  • 抑制要因
    • ペプチド治療の悪影響の想起
  • 機会
    • 世界中で新規ペプチド開発に向けた研究開発活動を継続中
    • 個別化医療への移行とペプチドバイオマーカーの特定
  • 課題
    • ペプチド治療の生産の複雑さと生物学的利用能の問題
• 市場セグメンテーション分析
  • 技術：複合ペプチドの合成における固相アプローチの利用増加
  • 薬剤クラス：1型と2型糖尿病のグルコース代謝を調節するためのインスリンの必要性の増加
  • 投与経路：急性期病院治療環境では、即時性と有効性のため静脈内投与の採用が増加
  • 用途：血圧調節に関与する内因性ペプチドの作用をシミュレートするために、心血管疾患におけるペプチド治療の使用を拡大
  • エンドユーザー：患者の状態に対応し管理するために病院やクリニックでペプチド治療の使用を拡大する
  • 製造タイプ：専門的な製造能力と生産を迅速に拡大する能力の必要性から、CMOの採用が増加
• 市場動向分析
  • 南北アメリカにおける医療セグメントの強化に向けた医薬品研究開発活動の拡大と政府投資の拡大
  • アジア太平洋における先進的な調査施設と技術への公的と民間による多額の投資
  • ペプチド製造能力の強化、新しい応用セグメントの開拓、欧州、中東、アフリカ地域における主要参入企業の存在
• 高インフレの累積的影響
• ポーターのファイブフォース分析
• バリューチェーンとクリティカルパス分析
• 規制枠組みの分析

第6章 ペプチド治療市場：技術別

• イントロダクション
• ハイブリッド相
• 液相
• 固相

第7章 ペプチド治療市場：薬剤クラス別

• イントロダクション
• 副腎皮質刺激ホルモン
• カルシトニン
• インスリン
• リュープロレリン
• オクトレオチド
• バソプレシン

第8章 ペプチド治療市場：投与経路別

• イントロダクション
• 静脈内投与
• 経鼻・経肺投与
• 経口投与
• 経皮投与

第9章 ペプチド治療市場：用途別

• イントロダクション
• 心血管疾患
• 胃腸障害
• 感染症
• 神経学的障害
• 腫瘍学

第10章 ペプチド治療市場：エンドユーザー別

• イントロダクション
• 病院・クリニック
• 長期介護施設
• 研究室

第11章 ペプチド治療市場製造タイプ別

• イントロダクション
• 契約製造組織
• 社内

第12章 南北アメリカのペプチド治療市場

• イントロダクション
• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第13章 アジア太平洋のペプチド治療市場

• イントロダクション
• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第14章 欧州・中東・アフリカのペプチド治療市場

• イントロダクション
• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第15章 競合情勢

• 市場シェア分析、2023年
• FPNVポジショニングマトリックス、2023年
• 競合シナリオ分析

第16章 競合ポートフォリオ

• 主要企業プロファイル
• 主要製品ポートフォリオ

LIST OF FIGURES

• FIGURE 1. PEPTIDE THERAPEUTICS MARKET RESEARCH PROCESS
• FIGURE 2. PEPTIDE THERAPEUTICS MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY REGION, 2023 VS 2030 (%)
• FIGURE 5. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. PEPTIDE THERAPEUTICS MARKET DYNAMICS
• FIGURE 7. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2023 VS 2030 (%)
• FIGURE 8. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 9. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2023 VS 2030 (%)
• FIGURE 10. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 11. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
• FIGURE 12. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 13. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
• FIGURE 14. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 15. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2023 VS 2030 (%)
• FIGURE 16. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 17. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY MANUFACTURING TYPE, 2023 VS 2030 (%)
• FIGURE 18. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY MANUFACTURING TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 19. AMERICAS PEPTIDE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 20. AMERICAS PEPTIDE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 21. UNITED STATES PEPTIDE THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 22. UNITED STATES PEPTIDE THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 23. ASIA-PACIFIC PEPTIDE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 24. ASIA-PACIFIC PEPTIDE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 25. EUROPE, MIDDLE EAST & AFRICA PEPTIDE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 26. EUROPE, MIDDLE EAST & AFRICA PEPTIDE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 27. PEPTIDE THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 28. PEPTIDE THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. PEPTIDE THERAPEUTICS MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, 2018-2023 (USD MILLION)
• TABLE 4. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, 2024-2030 (USD MILLION)
• TABLE 5. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY REGION, 2018-2023 (USD MILLION)
• TABLE 6. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY REGION, 2024-2030 (USD MILLION)
• TABLE 7. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 8. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 9. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY HYBRID PHASE, BY REGION, 2018-2023 (USD MILLION)
• TABLE 10. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY HYBRID PHASE, BY REGION, 2024-2030 (USD MILLION)
• TABLE 11. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY LIQUID PHASE, BY REGION, 2018-2023 (USD MILLION)
• TABLE 12. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY LIQUID PHASE, BY REGION, 2024-2030 (USD MILLION)
• TABLE 13. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY SOLID PHASE, BY REGION, 2018-2023 (USD MILLION)
• TABLE 14. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY SOLID PHASE, BY REGION, 2024-2030 (USD MILLION)
• TABLE 15. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
• TABLE 16. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
• TABLE 17. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY ADRENOCORTICOTROPIC HORMONE, BY REGION, 2018-2023 (USD MILLION)
• TABLE 18. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY ADRENOCORTICOTROPIC HORMONE, BY REGION, 2024-2030 (USD MILLION)
• TABLE 19. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY CALCITONIN, BY REGION, 2018-2023 (USD MILLION)
• TABLE 20. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY CALCITONIN, BY REGION, 2024-2030 (USD MILLION)
• TABLE 21. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY INSULIN, BY REGION, 2018-2023 (USD MILLION)
• TABLE 22. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY INSULIN, BY REGION, 2024-2030 (USD MILLION)
• TABLE 23. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY LEUPRORELIN, BY REGION, 2018-2023 (USD MILLION)
• TABLE 24. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY LEUPRORELIN, BY REGION, 2024-2030 (USD MILLION)
• TABLE 25. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY OCTREOTIDE, BY REGION, 2018-2023 (USD MILLION)
• TABLE 26. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY OCTREOTIDE, BY REGION, 2024-2030 (USD MILLION)
• TABLE 27. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY VASOPRESSIN, BY REGION, 2018-2023 (USD MILLION)
• TABLE 28. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY VASOPRESSIN, BY REGION, 2024-2030 (USD MILLION)
• TABLE 29. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
• TABLE 30. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
• TABLE 31. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY INTRAVENOUS ADMINISTRATION, BY REGION, 2018-2023 (USD MILLION)
• TABLE 32. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY INTRAVENOUS ADMINISTRATION, BY REGION, 2024-2030 (USD MILLION)
• TABLE 33. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY NASAL & PULMONARY ADMINISTRATION, BY REGION, 2018-2023 (USD MILLION)
• TABLE 34. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY NASAL & PULMONARY ADMINISTRATION, BY REGION, 2024-2030 (USD MILLION)
• TABLE 35. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY ORAL ADMINISTRATION, BY REGION, 2018-2023 (USD MILLION)
• TABLE 36. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY ORAL ADMINISTRATION, BY REGION, 2024-2030 (USD MILLION)
• TABLE 37. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY TRANSDERMAL ADMINISTRATION, BY REGION, 2018-2023 (USD MILLION)
• TABLE 38. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY TRANSDERMAL ADMINISTRATION, BY REGION, 2024-2030 (USD MILLION)
• TABLE 39. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 40. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 41. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY CARDIOVASCULAR DISORDERS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 42. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY CARDIOVASCULAR DISORDERS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 43. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY GASTROINTESTINAL DISORDERS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 44. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY GASTROINTESTINAL DISORDERS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 45. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISORDERS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 46. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISORDERS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 47. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 48. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 49. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2023 (USD MILLION)
• TABLE 50. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY ONCOLOGY, BY REGION, 2024-2030 (USD MILLION)
• TABLE 51. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
• TABLE 52. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
• TABLE 53. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 54. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 55. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY LONG-TERM CARE FACILITIES, BY REGION, 2018-2023 (USD MILLION)
• TABLE 56. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY LONG-TERM CARE FACILITIES, BY REGION, 2024-2030 (USD MILLION)
• TABLE 57. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY RESEARCH LABORATORIES, BY REGION, 2018-2023 (USD MILLION)
• TABLE 58. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY RESEARCH LABORATORIES, BY REGION, 2024-2030 (USD MILLION)
• TABLE 59. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY MANUFACTURING TYPE, 2018-2023 (USD MILLION)
• TABLE 60. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY MANUFACTURING TYPE, 2024-2030 (USD MILLION)
• TABLE 61. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY CONTRACT MANUFACTURING ORGANIZATION, BY REGION, 2018-2023 (USD MILLION)
• TABLE 62. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY CONTRACT MANUFACTURING ORGANIZATION, BY REGION, 2024-2030 (USD MILLION)
• TABLE 63. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY IN-HOUSE, BY REGION, 2018-2023 (USD MILLION)
• TABLE 64. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY IN-HOUSE, BY REGION, 2024-2030 (USD MILLION)
• TABLE 65. AMERICAS PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 66. AMERICAS PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 67. AMERICAS PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
• TABLE 68. AMERICAS PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
• TABLE 69. AMERICAS PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
• TABLE 70. AMERICAS PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
• TABLE 71. AMERICAS PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 72. AMERICAS PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 73. AMERICAS PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
• TABLE 74. AMERICAS PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
• TABLE 75. AMERICAS PEPTIDE THERAPEUTICS MARKET SIZE, BY MANUFACTURING TYPE, 2018-2023 (USD MILLION)
• TABLE 76. AMERICAS PEPTIDE THERAPEUTICS MARKET SIZE, BY MANUFACTURING TYPE, 2024-2030 (USD MILLION)
• TABLE 77. AMERICAS PEPTIDE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
• TABLE 78. AMERICAS PEPTIDE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
• TABLE 79. ARGENTINA PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 80. ARGENTINA PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 81. ARGENTINA PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
• TABLE 82. ARGENTINA PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
• TABLE 83. ARGENTINA PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
• TABLE 84. ARGENTINA PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
• TABLE 85. ARGENTINA PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 86. ARGENTINA PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 87. ARGENTINA PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
• TABLE 88. ARGENTINA PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
• TABLE 89. ARGENTINA PEPTIDE THERAPEUTICS MARKET SIZE, BY MANUFACTURING TYPE, 2018-2023 (USD MILLION)
• TABLE 90. ARGENTINA PEPTIDE THERAPEUTICS MARKET SIZE, BY MANUFACTURING TYPE, 2024-2030 (USD MILLION)
• TABLE 91. BRAZIL PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 92. BRAZIL PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 93. BRAZIL PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
• TABLE 94. BRAZIL PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
• TABLE 95. BRAZIL PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
• TABLE 96. BRAZIL PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
• TABLE 97. BRAZIL PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 98. BRAZIL PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 99. BRAZIL PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
• TABLE 100. BRAZIL PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
• TABLE 101. BRAZIL PEPTIDE THERAPEUTICS MARKET SIZE, BY MANUFACTURING TYPE, 2018-2023 (USD MILLION)
• TABLE 102. BRAZIL PEPTIDE THERAPEUTICS MARKET SIZE, BY MANUFACTURING TYPE, 2024-2030 (USD MILLION)
• TABLE 103. CANADA PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 104. CANADA PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 105. CANADA PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
• TABLE 106. CANADA PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
• TABLE 107. CANADA PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
• TABLE 108. CANADA PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
• TABLE 109. CANADA PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 110. CANADA PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 111. CANADA PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
• TABLE 112. CANADA PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
• TABLE 113. CANADA PEPTIDE THERAPEUTICS MARKET SIZE, BY MANUFACTURING TYPE, 2018-2023 (USD MILLION)
• TABLE 114. CANADA PEPTIDE THERAPEUTICS MARKET SIZE, BY MANUFACTURING TYPE, 2024-2030 (USD MILLION)
• TABLE 115. MEXICO PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 116. MEXICO PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 117. MEXICO PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
• TABLE 118. MEXICO PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
• TABLE 119. MEXICO PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
• TABLE 120. MEXICO PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
• TABLE 121. MEXICO PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 122. MEXICO PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 123. MEXICO PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
• TABLE 124. MEXICO PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
• TABLE 125. MEXICO PEPTIDE THERAPEUTICS MARKET SIZE, BY MANUFACTURING TYPE, 2018-2023 (USD MILLION)
• TABLE 126. MEXICO PEPTIDE THERAPEUTICS MARKET SIZE, BY MANUFACTURING TYPE, 2024-2030 (USD MILLION)
• TABLE 127. UNITED STATES PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 128. UNITED STATES PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 129. UNITED STATES PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
• TABLE 130. UNITED STATES PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
• TABLE 131. UNITED STATES PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
• TABLE 132. UNITED STATES PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
• TABLE 133. UNITED STATES PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 134. UNITED STATES PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 135. UNITED STATES PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
• TABLE 136. UNITED STATES PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
• TABLE 137. UNITED STATES PEPTIDE THERAPEUTICS MARKET SIZE, BY MANUFACTURING TYPE, 2018-2023 (USD MILLION)
• TABLE 138. UNITED STATES PEPTIDE THERAPEUTICS MARKET SIZE, BY MANUFACTURING TYPE, 2024-2030 (USD MILLION)
• TABLE 139. UNITED STATES PEPTIDE THERAPEUTICS MARKET SIZE, BY STATE, 2018-2023 (USD MILLION)
• TABLE 140. UNITED STATES PEPTIDE THERAPEUTICS MARKET SIZE, BY STATE, 2024-2030 (USD MILLION)
• TABLE 141. ASIA-PACIFIC PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 142. ASIA-PACIFIC PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 143. ASIA-PACIFIC PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
• TABLE 144. ASIA-PACIFIC PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
• TABLE 145. ASIA-PACIFIC PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
• TABLE 146. ASIA-PACIFIC PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
• TABLE 147. ASIA-PACIFIC PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 148. ASIA-PACIFIC PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 149. ASIA-PACIFIC PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
• TABLE 150. ASIA-PACIFIC PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
• TABLE 151. ASIA-PACIFIC PEPTIDE THERAPEUTICS MARKET SIZE, BY MANUFACTURING TYPE, 2018-2023 (USD MILLION)
• TABLE 152. ASIA-PACIFIC PEPTIDE THERAPEUTICS MARKET SIZE, BY MANUFACTURING TYPE, 2024-2030 (USD MILLION)
• TABLE 153. ASIA-PACIFIC PEPTIDE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
• TABLE 154. ASIA-PACIFIC PEPTIDE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
• TABLE 155. AUSTRALIA PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 156. AUSTRALIA PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 157. AUSTRALIA PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
• TABLE 158. AUSTRALIA PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
• TABLE 159. AUSTRALIA PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
• TABLE 160. AUSTRALIA PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
• TABLE 161. AUSTRALIA PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 162. AUSTRALIA PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 163. AUSTRALIA PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
• TABLE 164. AUSTRALIA PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
• TABLE 165. AUSTRALIA PEPTIDE THERAPEUTICS MARKET SIZE, BY MANUFACTURING TYPE, 2018-2023 (USD MILLION)
• TABLE 166. AUSTRALIA PEPTIDE THERAPEUTICS MARKET SIZE, BY MANUFACTURING TYPE, 2024-2030 (USD MILLION)
• TABLE 167. CHINA PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 168. CHINA PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 169. CHINA PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
• TABLE 170. CHINA PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
• TABLE 171. CHINA PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
• TABLE 172. CHINA PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
• TABLE 173. CHINA PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 174. CHINA PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 175. CHINA PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
• TABLE 176. CHINA PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
• TABLE 177. CHINA PEPTIDE THERAPEUTICS MARKET SIZE, BY MANUFACTURING TYPE, 2018-2023 (USD MILLION)
• TABLE 178. CHINA PEPTIDE THERAPEUTICS MARKET SIZE, BY MANUFACTURING TYPE, 2024-2030 (USD MILLION)
• TABLE 179. INDIA PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 180. INDIA PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 181. INDIA PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
• TABLE 182. INDIA PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
• TABLE 183. INDIA PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
• TABLE 184. INDIA PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
• TABLE 185. INDIA PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 186. INDIA PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 187. INDIA PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
• TABLE 188. INDIA PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
• TABLE 189. INDIA PEPTIDE THERAPEUTICS MARKET SIZE, BY MANUFACTURING TYPE, 2018-2023 (USD MILLION)
• TABLE 190. INDIA PEPTIDE THERAPEUTICS MARKET SIZE, BY MANUFACTURING TYPE, 2024-2030 (USD MILLION)
• TABLE 191. INDONESIA PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 192. INDONESIA PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 193. INDONESIA PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
• TABLE 194. INDONESIA PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
• TABLE 195. INDONESIA PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
• TABLE 196. INDONESIA PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
• TABLE 197. INDONESIA PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 198. INDONESIA PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 199. INDONESIA PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
• TABLE 200. INDONESIA PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
• TABLE 201. INDONESIA PEPTIDE THERAPEUTICS MARKET SIZE, BY MANUFACTURING TYPE, 2018-2023 (USD MILLION)
• TABLE 202. INDONESIA PEPTIDE THERAPEUTICS MARKET SIZE, BY MANUFACTURING TYPE, 2024-2030 (USD MILLION)
• TABLE 203. JAPAN PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 204. JAPAN PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 205. JAPAN PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
• TABLE 206. JAPAN PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
• TABLE 207. JAPAN PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
• TABLE 208. JAPAN PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
• TABLE 209. JAPAN PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 210. JAPAN PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 211. JAPAN PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
• TABLE 212. JAPAN PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
• TABLE 213. JAPAN PEPTIDE THERAPEUTICS MARKET SIZE, BY MANUFACTURING TYPE, 2018-2023 (USD MILLION)
• TABLE 214. JAPAN PEPTIDE THERAPEUTICS MARKET SIZE, BY MANUFACTURING TYPE, 2024-2030 (USD MILLION)
• TABLE 215. MALAYSIA PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 216. MALAYSIA PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 217. MALAYSIA PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
• TABLE 218. MALAYSIA PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
• TABLE 219. MALAYSIA PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
• TABLE 220. MALAYSIA PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
• TABLE 221. MALAYSIA PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 222. MALAYSIA PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 223. MALAYSIA PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
• TABLE 224. MALAYSIA PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
• TABLE 225. MALAYSIA PEPTIDE THERAPEUTICS MARKET SIZE, BY MANUFACTURING TYPE, 2018-2023 (USD MILLION)
• TABLE 226. MALAYSIA PEPTIDE THERAPEUTICS MARKET SIZE, BY MANUFACTURING TYPE, 2024-2030 (USD MILLION)
• TABLE 227. PHILIPPINES PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 228. PHILIPPINES PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 229. PHILIPPINES PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
• TABLE 230. PHILIPPINES PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
• TABLE 231. PHILIPPINES PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
• TABLE 232. PHILIPPINES PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
• TABLE 233. PHILIPPINES PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 234. PHILIPPINES PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 235. PHILIPPINES PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
• TABLE 236. PHILIPPINES PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
• TABLE 237. PHILIPPINES PEPTIDE THERAPEUTICS MARKET SIZE, BY MANUFACTURING TYPE, 2018-2023 (USD MILLION)
• TABLE 238. PHILIPPINES PEPTIDE THERAPEUTICS MARKET SIZE, BY MANUFACTURING TYPE, 2024-2030 (USD MILLION)
• TABLE 239. SINGAPORE PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 240. SINGAPORE PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 241. SINGAPORE PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
• TABLE 242. SINGAPORE PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
• TABLE 243. SINGAPORE PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
• TABLE 244. SINGAPORE PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
• TABLE 245. SINGAPORE PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 246. SINGAPORE PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 247. SINGAPORE PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
• TABLE 248. SINGAPORE PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
• TABLE 249. SINGAPORE PEPTIDE THERAPEUTICS MARKET SIZE, BY MANUFACTURING TYPE, 2018-2023 (USD MILLION)
• TABLE 250. SINGAPORE PEPTIDE THERAPEUTICS MARKET SIZE, BY MANUFACTURING TYPE, 2024-2030 (USD MILLION)
• TABLE 251. SOUTH KOREA PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 252. SOUTH KOREA PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 253. SOUTH KOREA PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
• TABLE 254. SOUTH KOREA PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
• TABLE 255. SOUTH KOREA PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
• TABLE 256. SOUTH KOREA PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
• TABLE 257. SOUTH KOREA PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 258. SOUTH KOREA PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 259. SOUTH KOREA PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
• TABLE 260. SOUTH KOREA PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
• TABLE 261. SOUTH KOREA PEPTIDE THERAPEUTICS MARKET SIZE, BY MANUFACTURING TYPE, 2018-2023 (USD MILLION)
• TABLE 262. SOUTH KOREA PEPTIDE THERAPEUTICS MARKET SIZE, BY MANUFACTURING TYPE, 2024-2030 (USD MILLION)
• TABLE 263. TAIWAN PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 264. TAIWAN PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 265. TAIWAN PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
• TABLE 266. TAIWAN PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
• TABLE 267. TAIWAN PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
• TABLE 268. TAIWAN PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
• TABLE 269. TAIWAN PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 270. TAIWAN PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 271. TAIWAN PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
• TABLE 272. TAIWAN PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
• TABLE 273. TAIWAN PEPTIDE THERAPEUTICS MARKET SIZE, BY MANUFACTURING TYPE, 2018-2023 (USD MILLION)
• TABLE 274. TAIWAN PEPTIDE THERAPEUTICS MARKET SIZE, BY MANUFACTURING TYPE, 2024-2030 (USD MILLION)
• TABLE 275. THAILAND PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 276. THAILAND PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 277. THAILAND PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
• TABLE 278. THAILAND PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
• TABLE 279. THAILAND PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
• TABLE 280. THAILAND PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
• TABLE 281. THAILAND PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 282. THAILAND PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 283. THAILAND PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
• TABLE 284. THAILAND PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
• TABLE 285. THAILAND PEPTIDE THERAPEUTICS MARKET SIZE, BY MANUFACTURING TYPE, 2018-2023 (USD MILLION)
• TABLE 286. THAILAND PEPTIDE THERAPEUTICS MARKET SIZE, BY MANUFACTURING TYPE, 2024-2030 (USD MILLION)
• TABLE 287. VIETNAM PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 288. VIETNAM PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 289. VIETNAM PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
• TABLE 290. VIETNAM PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
• TABLE 291. VIETNAM PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
• TABLE 292. VIETNAM PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
• TABLE 293. VIETNAM PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 294. VIETNAM PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 295. VIETNAM PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
• TABLE 296. VIETNAM PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
• TABLE 297. VIETNAM PEPTIDE THERAPEUTICS MARKET SIZE, BY MANUFACTURING TYPE, 2018-2023 (USD MILLION)
• TABLE 298. VIETNAM PEPTIDE THERAPEUTICS MARKET SIZE, BY MANUFACTURING TYPE, 2024-2030 (USD MILLION)
• TABLE 299. EUROPE, MIDDLE EAST & AFRICA PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 300. EUROPE, MIDDLE EAST & AFRICA PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 301. EUROPE, MIDDLE EAST & AFRICA PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
• TABLE 302. EUROPE, MIDDLE EAST & AFRICA PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
• TABLE 303. EUROPE, MIDDLE EAST & AFRICA PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
• TABLE 304. EUROPE, MIDDLE EAST & AFRICA PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
• TABLE 305. EUROPE, MIDDLE EAST & AFRICA PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 306. EUROPE, MIDDLE EAST & AFRICA PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 307. EUROPE, MIDDLE EAST & AFRICA PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
• TABLE 308. EUROPE, MIDDLE EAST & AFRICA PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
• TABLE 309. EUROPE, MIDDLE EAST & AFRICA PEPTIDE THERAPEUTICS MARKET SIZE, BY MANUFACTURING TYPE, 2018-2023 (USD MILLION)
• TABLE 310. EUROPE, MIDDLE EAST & AFRICA PEPTIDE THERAPEUTICS MARKET SIZE, BY MANUFACTURING TYPE, 2024-2030 (USD MILLION)
• TABLE 311. EUROPE, MIDDLE EAST & AFRICA PEPTIDE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
• TABLE 312. EUROPE, MIDDLE EAST & AFRICA PEPTIDE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
• TABLE 313. DENMARK PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 314. DENMARK PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 315. DENMARK PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
• TABLE 316. DENMARK PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
• TABLE 317. DENMARK PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
• TABLE 318. DENMARK PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
• TABLE 319. DENMARK PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 320. DENMARK PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 321. DENMARK PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
• TABLE 322. DENMARK PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
• TABLE 323. DENMARK PEPTIDE THERAPEUTICS MARKET SIZE, BY MANUFACTURING TYPE, 2018-2023 (USD MILLION)
• TABLE 324. DENMARK PEPTIDE THERAPEUTICS MARKET SIZE, BY MANUFACTURING TYPE, 2024-2030 (USD MILLION)
• TABLE 325. EGYPT PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 326. EGYPT PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 327. EGYPT PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
• TABLE 328. EGYPT PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
• TABLE 329. EGYPT PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
• TABLE 330. EGYPT PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
• TABLE 331. EGYPT PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 332. EGYPT PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 333. EGYPT PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
• TABLE 334. EGYPT PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)

TABLE

[196 Pages Report] The Peptide Therapeutics Market size was estimated at USD 33.06 billion in 2023 and expected to reach USD 35.76 billion in 2024, at a CAGR 8.35% to reach USD 57.97 billion by 2030.

Peptide therapeutics use short chains of amino acids to treat or control various diseases and medical conditions. These biologically active molecules possess unique properties, making them an efficient drug development and pharmaceutical research option. The surging prevalence of chronic diseases, including cancer and diabetes, is raising the need for effective treatment options and an improved understanding of protein-protein interactions leading to targeted therapies. The growing investment in research & development activities and a robust clinical pipeline with therapeutic candidates result in novel peptide therapeutics being developed. However, the inherent instability of peptides and the high cost of manufacturing peptides may adversely impact the development of peptide therapeutics. Moreover, recent developments in drug delivery systems and the development of new peptides are expected to expand the potential applications for peptides.

Technology: Rising utilization of solid phase approach for synthesis of complex peptides

The hybrid phase approach combines liquid-phase and solid-phase synthesis features to enhance efficiency and scalability while maintaining high purity levels for peptide production. This technique is favored while developing complex or large peptides due to its ability to overcome challenges associated with traditional methods. Liquid phase peptide synthesis (LPPS) involves coupling amino acids in solution using various chemical reactions. LPPS is suitable for small-scale production of short to medium-length peptides due to its relatively fast reaction rates compared to solid-phase methods. Solid phase peptide synthesis (SPPS) involves attaching the first amino acid to a solid resin support, followed by the sequential addition of subsequent amino acids. This method is widely preferred due to its ability to synthesize longer and more complex peptides and ease of purification and scalability. Hybrid phase technology is preferred for developing large or complex peptides due to its combined advantages from liquid and solid phases. Liquid phase synthesis is primarily used for small-scale, short- to medium-length peptide production. Solid-phase peptide synthesis is widely favored due to its versatility in synthesizing longer and more complex peptides while offering easy purification and scalability options.

Drug Class: Increasing need for insulin to regulate glucose metabolism for type 1 and type 2 diabetes

Adrenocorticotropic hormone (ACTH) is a polypeptide hormone secreted and produced by the anterior pituitary gland. Therapeutically, ACTH is utilized in managing certain disorders where there is a need to stimulate cortisol production. This includes treatment for conditions such as adrenal insufficiency and certain inflammatory disorders that respond to increased cortisol levels. The exogenous form used in therapy provides a direct stimulus to the adrenal cortex by simulating the action of occurring ACTH, encouraging it to secrete cortisol, thereby exerting anti-inflammatory and immunostimulatory effects. Calcitonin is critical in calcium and phosphorus metabolism. It is produced in humans primarily by the parafollicular thyroid gland cells. Therapeutic forms of calcitonin, derived from salmon or synthetically produced, are utilized primarily in treating postmenopausal osteoporosis, Paget's disease, and hypercalcemia. By inhibiting osteoclast activity, calcitonin reduces bone resorption, thereby decreasing blood calcium levels. Insulin is a fundamental peptide hormone critical for regulating glucose metabolism produced by the beta cells of the pancreas, facilitating glucose uptake from the blood into the muscle, liver, and fat cells. In the therapeutic context, insulin is vital in managing diabetes mellitus, both type 1 and type 2, where the body's ability to produce or respond to insulin is impaired. Leuprorelin is a synthetic analog of gonadotropin-releasing hormone (GnRH) and functions as a potent inhibitor of gonadotropin secretion when used in continuous administration. It is employed in the treatment of hormone-responsive cancers such as prostate cancer in men and endometriosis and uterine fibroids in women. Octreotide is a synthetic octapeptide analog of the natural hormone somatostatin, possessing similar but longer-lasting pharmacological effects. It is primarily used in the management of acromegaly, a condition characterized by excess production of growth hormone, and in the control of symptoms caused by certain types of tumors that secrete hormones, such as carcinoid tumors and vasoactive intestinal peptide-secreting adenomas (VIPomas). Octreotide works by inhibiting the secretion of various hormones, including growth hormone, gastrin, insulin, and glucagon. Vasopressin, also referred to as antidiuretic hormone (ADH), is a peptide hormone that is secreted by the posterior pituitary gland and produced by the hypothalamus. ADH is critical in regulating the body's water retention by increasing water reabsorption in the kidney's collecting ducts. In a therapeutic setting, vasopressin and its analogs are used to treat diabetes insipidus, a condition characterized by excess thirst and the production of large amounts of diluted urine, and for managing variceal bleeding due to its vasoconstrictive properties.

Route of Administration: Rising adoption of intravenous administration due to peptide therapeutics immediacy and effectiveness in acute hospital care settings

Intravenous (IV) administration of peptide therapeutics ensures direct delivery into the bloodstream, facilitating immediate bioavailability. This route is particularly advantageous for peptides that are poorly absorbed through the gastrointestinal tract or extensively metabolized when administered by other routes. IV administration is critical for peptides used in acute care settings or where rapid onset of action is necessary. However, it requires clinical infrastructure and skilled personnel to administer, potentially limiting its applicability to outpatient settings or chronic treatments. Nasal & pulmonary routes offer non-invasive administration alternatives for peptide therapeutics, capable of providing efficient absorption and immediate action for certain conditions. Nasal administration is particularly suited for peptides targeting the central nervous system, leveraging the nose-to-brain pathway. Pulmonary administration is ideal for peptides intended for respiratory ailments, allowing direct delivery to the lungs. Both methods bypass first-pass metabolism, potentially increasing the therapeutic's bioavailability. Oral administration is a preferred route for drug delivery, attributed to its convenience, patient compliance, and cost-effectiveness. Peptides are subject to enzymatic degradation within the gastrointestinal tract and suffer from poor permeability across the intestinal epithelium. Advances in pharmaceutical sciences, such as enzyme inhibitors, permeation enhancers, and nanoparticle delivery systems, have shown promise in overcoming these hurdles, albeit with varying degrees of success. Transdermal delivery of peptide therapeutics offers a compelling balance between efficacy and patient compliance, eliminating the need for injections or specialized inhalation devices. This route is particularly advantageous for chronic conditions requiring sustained release of medication. Advances in transdermal technologies, including microneedles, iontophoresis, and ultrasound, have improved the transport of peptides across the skin barrier. Formulation strategies that enhance skin permeability and peptide stability are central to the successful development of transdermal peptide therapeutics.

Application: Widening use of peptide therapeutics in cardiovascular disorders to simulate the action of endogenous peptides involved in blood pressure regulation

In cardiovascular disorders, peptide therapeutics have been used for their precise mechanisms of action, which can effectively modulate vascular function, blood pressure, and coagulation pathways. Anticoagulant peptides are utilized to prevent thrombosis, a critical risk factor for myocardial infarction and stroke. In gastrointestinal (GI) disorders, peptide therapeutics present an avenue for targeted treatment options. In addition, peptides that mimic or inhibit gastrointestinal hormones can regulate motility, absorption, and secretion within the GI tract, addressing symptoms of various disorders. Their targeted action can aid in managing conditions stemming from hormonal imbalances or disruptions in GI-related disorders. Peptide therapeutics bring a novel approach to managing infectious disorders, especially in an era of increasing antibiotic resistance. Antimicrobial peptides (AMPs) offer a broad-spectrum antimicrobial activity, targeting bacteria, fungi, and even some viruses by disrupting their cellular membranes. Their mode of action reduces the likelihood of resistance development, making them crucial contenders in the fight against drug-resistant infections. In neurological disorders, peptide therapeutics are being explored for their potential for crossing the blood-brain barrier (BBB) and delivering neuroprotective effects directly to the central nervous system (CNS). Peptides target specific neurotransmitter systems, providing opportunities for the treatment of diseases, including Alzheimer's, Parkinson's, and multiple sclerosis. In oncology, peptide therapeutics represent a fast-growing area, with peptides being investigated for their anti-cancer properties, including direct cytotoxic effects on cancer cells, inhibition of angiogenesis, and vehicles for targeted drug delivery. Tumor-homing peptides are able to selectively deliver chemotherapeutic agents or radionuclides to tumor cells, minimizing damage to healthy tissues and enhancing treatment efficacy.

End User: Expanding the use of peptide therapeutics in hospitals and clinics to address and manage patient conditions

In hospitals & clinics, peptide therapeutics are primarily utilized for direct patient care. They are employed in treating numerous conditions, including cancer, metabolic disorders, cardiovascular diseases, and infectious diseases. Peptide drugs offer a targeted approach to treatment due to their high specificity and potency with relatively low toxicity, allowing for higher efficacy with potentially fewer side effects compared to traditional small molecule drugs. Their application in hospitals & clinics continuously evolves with advances in peptide engineering and drug delivery technologies, enhancing their effectiveness and patient compliance. Long-term care facilities prioritize treatments that ensure the well-being of patients over extended periods, often focusing on management rather than cure. Peptide therapeutics used in long-term care facilities need to have minimal side effects and require less frequent dosing schedules to accommodate the caregiving environment. Research laboratories are crucial in the early stages of peptide therapeutic development. Researchers focus on identifying new bioactive peptides, elucidating their mechanisms of action, and optimizing their properties for therapeutic use. This involves cutting-edge molecular biology, biochemistry, and pharmacology techniques to design, synthesize, and assess the activity of peptide candidates.

Manufacturing Type: Increasing adoption of CMOs owing to the need for specialized manufacturing capabilities and the ability to scale production rapidly

Contract manufacturing organizations provide essential services in the production of peptide therapeutics, serving pharmaceutical and biotech companies that either do not possess the necessary in-house production facilities or choose to outsource manufacturing to focus on core competencies. CMOs offer various services, from synthesizing peptides in small quantities for research purposes to large-scale production for commercial use. They possess the technical expertise, advanced technologies, and regulatory knowledge required for the efficient and compliant manufacture of peptide therapeutics. In-house production refers to the scenario where pharmaceutical or biotechnology companies have the facilities and resources to manufacture peptide therapeutics. This approach allows companies to maintain direct control over the production processes, quality control, and supply chain management, potentially reducing risks associated with reliance on external suppliers. Large pharmaceutical companies often establish in-house production facilities with the financial resources to invest in the necessary infrastructure and skilled personnel. This model facilitates closer integration between research and development activities and manufacturing, which can be advantageous in rapidly evolving therapeutic areas.

Regional Insights

The peptide therapeutics market is evolving in the Americas due to well-established pharmaceutical industries, increased research activities, and a growing number of approved peptide drugs. Patent activity in this region is notable, with several major pharmaceutical companies headquartered in the area. In recent years, investments in innovative peptide formulations have increased, indicating a robust market potential for new therapeutic approaches. The rising prevalence of chronic disease, improving healthcare infrastructure, and growing awareness regarding peptide therapeutics are encouraging the growth of the peptide therapeutics market in the APAC region. In addition, ongoing advancements and the development of efficient, scalable, and cost-effective synthetic strategies for producing peptides are anticipated to encourage the adoption of peptide therapeutics globally. The peptide therapeutics market is developing in the EMEA region owing to the regulatory framework supporting innovation within biotechnology and funding research projects related to peptide therapeutics. The European Union demonstrates a well-established market for peptide therapeutics, supported by comprehensive healthcare systems and a high degree of awareness regarding advanced treatment options. The EU's regulatory framework, through the European Medicines Agency (EMA), has been instrumental in approving and monitoring peptide-based drugs. The peptide therapeutics market in the African region is currently growing steadily, characterized by growing research activities and increasing awareness toward advanced therapeutic options.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Peptide Therapeutics Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Peptide Therapeutics Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Peptide Therapeutics Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., AmbioPharm, Inc., Amgen Inc., Amide Technologies, Inc., AstraZeneca PLC, Bachem Holding AG, Biosynth Ltd., Bristol Myers Squibb Company, Cidara Therapeutics, Inc., Corden Pharma International GmbH, Cybrexa, Inc., Eccogene, Eli Lilly and Company, Exelixis, Inc., F. Hoffmann-La Roche Ltd., GlaxoSmithKline PLC, Ipsen Group, IRBM S.p.A., Ironwood Pharmaceuticals, Inc., Merck KGaA, Novartis AG, Novo Nordisk A/S, Otsuka Pharmaceutical Co., Ltd., Peptidream Co., Ltd., Perpetual Medicines Corporation, Pfizer Inc., Piramal Pharma Limited, PolyPeptide Group AG, RELIEF THERAPEUTICS Holding SA, Sanofi S.A., Sanyou Biopharmaceuticals Co., Ltd., Shanghai Full-Life Technologies Co, Ltd., Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Limited, WuXi AppTec Co., Ltd., and Zealand Pharma A/S.

Market Segmentation & Coverage

This research report categorizes the Peptide Therapeutics Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Technology
  • Hybrid Phase
  • Liquid Phase
  • Solid Phase

• Drug Class
  • Adrenocorticotropic Hormone
  • Calcitonin
  • Insulin
  • Leuprorelin
  • Octreotide
  • Vasopressin

• Route of Administration
  • Intravenous Administration
  • Nasal & Pulmonary Administration
  • Oral Administration
  • Transdermal Administration

• Application
  • Cardiovascular Disorders
  • Gastrointestinal Disorders
  • Infectious Disorders
  • Neurological Disorders
  • Oncology

• End User
  • Hospitals & Clinics
  • Long-term Care Facilities
  • Research Laboratories

• Manufacturing Type
  • Contract Manufacturing Organization
  • In-house

• Region
  • Americas
    • Argentina
    • Brazil
    • Canada
    • Mexico
    • United States
      • California
      • Florida
      • Illinois
      • Indiana
      • Maryland
      • Massachusetts
      • Minnesota
      • New Jersey
      • New York
      • North Carolina
      • Ohio
      • Pennsylvania
      • Texas
  • Asia-Pacific
    • Australia
    • China
    • India
    • Indonesia
    • Japan
    • Malaysia
    • Philippines
    • Singapore
    • South Korea
    • Taiwan
    • Thailand
    • Vietnam

• Europe, Middle East & Africa
  • Denmark
  • Egypt
  • Finland
  • France
  • Germany
  • Israel
  • Italy
  • Netherlands
  • Nigeria
  • Norway
  • Poland
  • Qatar
  • Russia
  • Saudi Arabia
  • South Africa
  • Spain
  • Sweden
  • Switzerland
  • Turkey
  • United Arab Emirates
  • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Peptide Therapeutics Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Peptide Therapeutics Market?

3. What are the technology trends and regulatory frameworks in the Peptide Therapeutics Market?

4. What is the market share of the leading vendors in the Peptide Therapeutics Market?

5. Which modes and strategic moves are suitable for entering the Peptide Therapeutics Market?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Prevalence of chronic diseases and need for effective therapeutic options
    • 5.1.1.2. Exponential use of peptides in aesthetic dermatology
  • 5.1.2. Restraints
    • 5.1.2.1. Adverse recalls of peptide therapeutics
  • 5.1.3. Opportunities
    • 5.1.3.1. Ongoing R&D activities for new peptide development worldwide
    • 5.1.3.2. Shift toward personalized medicine and identification of peptide biomarkers
  • 5.1.4. Challenges
    • 5.1.4.1. Production complexity and bioavailability issues of peptide therapeutics
• 5.2. Market Segmentation Analysis
  • 5.2.1. Technology: Rising utilization of solid phase approach for synthesis of complex peptides
  • 5.2.2. Drug Class: Increasing need for insulin to regulate glucose metabolism for type 1 and type 2 diabetes
  • 5.2.3. Route of Administration: Rising adoption of intravenous administration due to peptide therapeutics immediacy and effectiveness in acute hospital care settings
  • 5.2.4. Application: Widening use of peptide therapeutics in cardiovascular disorders to simulate the action of endogenous peptides involved in blood pressure regulation
  • 5.2.5. End User: Expanding the use of peptide therapeutics in hospitals and clinics to address and manage patient conditions
  • 5.2.6. Manufacturing Type: Increasing adoption of CMOs owing to the need for specialized manufacturing capabilities and the ability to scale production rapidly
• 5.3. Market Trend Analysis
  • 5.3.1. Expanding pharmaceutical R&D activities and growing government investment to strengthen the healthcare sector in the Americas
  • 5.3.2. Significant public and private investment in advanced research facilities and technologies in the Asia-Pacific region
  • 5.3.3. Enhancement in peptide manufacturing capabilities, exploring new application areas, and presence of major players in the EMEA region
• 5.4. Cumulative Impact of High Inflation
• 5.5. Porter's Five Forces Analysis
  • 5.5.1. Threat of New Entrants
  • 5.5.2. Threat of Substitutes
  • 5.5.3. Bargaining Power of Customers
  • 5.5.4. Bargaining Power of Suppliers
  • 5.5.5. Industry Rivalry
• 5.6. Value Chain & Critical Path Analysis
• 5.7. Regulatory Framework Analysis

6. Peptide Therapeutics Market, by Technology

• 6.1. Introduction
• 6.2. Hybrid Phase
• 6.3. Liquid Phase
• 6.4. Solid Phase

7. Peptide Therapeutics Market, by Drug Class

• 7.1. Introduction
• 7.2. Adrenocorticotropic Hormone
• 7.3. Calcitonin
• 7.4. Insulin
• 7.5. Leuprorelin
• 7.6. Octreotide
• 7.7. Vasopressin

8. Peptide Therapeutics Market, by Route of Administration

• 8.1. Introduction
• 8.2. Intravenous Administration
• 8.3. Nasal & Pulmonary Administration
• 8.4. Oral Administration
• 8.5. Transdermal Administration

9. Peptide Therapeutics Market, by Application

• 9.1. Introduction
• 9.2. Cardiovascular Disorders
• 9.3. Gastrointestinal Disorders
• 9.4. Infectious Disorders
• 9.5. Neurological Disorders
• 9.6. Oncology

10. Peptide Therapeutics Market, by End User

• 10.1. Introduction
• 10.2. Hospitals & Clinics
• 10.3. Long-term Care Facilities
• 10.4. Research Laboratories

11. Peptide Therapeutics Market, by Manufacturing Type

• 11.1. Introduction
• 11.2. Contract Manufacturing Organization
• 11.3. In-house

12. Americas Peptide Therapeutics Market

• 12.1. Introduction
• 12.2. Argentina
• 12.3. Brazil
• 12.4. Canada
• 12.5. Mexico
• 12.6. United States

13. Asia-Pacific Peptide Therapeutics Market

• 13.1. Introduction
• 13.2. Australia
• 13.3. China
• 13.4. India
• 13.5. Indonesia
• 13.6. Japan
• 13.7. Malaysia
• 13.8. Philippines
• 13.9. Singapore
• 13.10. South Korea
• 13.11. Taiwan
• 13.12. Thailand
• 13.13. Vietnam

14. Europe, Middle East & Africa Peptide Therapeutics Market

• 14.1. Introduction
• 14.2. Denmark
• 14.3. Egypt
• 14.4. Finland
• 14.5. France
• 14.6. Germany
• 14.7. Israel
• 14.8. Italy
• 14.9. Netherlands
• 14.10. Nigeria
• 14.11. Norway
• 14.12. Poland
• 14.13. Qatar
• 14.14. Russia
• 14.15. Saudi Arabia
• 14.16. South Africa
• 14.17. Spain
• 14.18. Sweden
• 14.19. Switzerland
• 14.20. Turkey
• 14.21. United Arab Emirates
• 14.22. United Kingdom

15. Competitive Landscape

• 15.1. Market Share Analysis, 2023
• 15.2. FPNV Positioning Matrix, 2023
• 15.3. Competitive Scenario Analysis
  • 15.3.1. Expansion of GMP Capacities at CordenPharma Frankfurt: Elevating Early-Phase Peptide API Manufacturing
  • 15.3.2. Revolutionizing Peptide Therapeutics: Orbis Medicines Innovates for Oral Drug Delivery
  • 15.3.3. Expanding Facilities in Peptide Therapeutic Production: WuXi AppTec's Strategic Growth
  • 15.3.4. Glenmark Pharmaceuticals Announces Biosimilar Liraglutide Launch in India to Revolutionize Anti-Diabetic Treatment
  • 15.3.5. Amide Technologies' Novel Manufacturing Platform and Strategic Capital Advancement
  • 15.3.6. Strategic Acquisition Elevates Pharmathen's Position in the Peptide Therapeutics Market
  • 15.3.7. Biosynth Solidifies Market Position with Strategic Acquisition of Pepceuticals
  • 15.3.8. Strategic Collaboration between PeptiDream and Genentech to Advance Peptide-Radioisotope Therapeutics
  • 15.3.9. Merck and IRBM Forge Forward in Peptide Therapeutics: A Partnership to Expand and Innovate in Biopharmaceuticals
  • 15.3.10. Fujitsu Launches Pioneering Bio-Drug Design Accelerator Focused on Advancing Peptide Therapeutics in Cancer and CNS Regeneration
  • 15.3.11. Comprehensive Support for Peptide Therapeutics Development from Conception to Manufacturing for Introducing SynCrest's CRDMO Service

16. Competitive Portfolio

• 16.1. Key Company Profiles
• 16.2. Key Product Portfolio